SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Tiensuu Janson Eva)
 

Sökning: WFRF:(Tiensuu Janson Eva) > (2020-2024) > Prospective Study o...

  • Dam, GitteAarhus Univ Hosp, Dept Gastroenterol & Hepatol, Neuroendocrine Tumour Ctr Excellence, DK-8200 Aarhus N, Denmark. (författare)

Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2019-10-02
  • S. Karger AG,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-411465
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-411465URI
  • https://doi.org/10.1159/000503833DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Ulrich Knigge and Eva Tiensuu Janson shared last co-authorship.
  • Background: Retrospective studies are conflicting but most of them report that an increase in plasma chromogranin A (CgA) predicts tumor progression in neuroendocrine tumor (NET) patients. Prospectively, we investigated if a change in plasma CgA is associated with tumor burden changes in NET patients with disseminated disease. Methods: We included 239 patients treated at 5 NET centers from December 2010 to December 2013. CgA was measured within 6 weeks of a CT or MRI in a patient undergoing at least 2 scan examinations performed over a period of 1-24 months. In a post hoc analysis, CgA measured 3-6 months prior to the CT/MRI was analyzed. Changes in tumor size were evaluated by RECIST1.1. A 25% change in CgA was chosen to discriminate between increased, decreased, or unchanged levels. Results: In 671 events (2 CT/MRI scans and 2 corresponding CgA measurements), we found a weak positive correlation between the RECIST 1.1 responses and change in plasma CgA from baseline (Spearman's rank correlation coefficient: 0.15; p < 0.05). Of 304 events in the post hoc analysis, 58 showed progression, 228 showed stable disease, and 18 showed regression, with a median change in CgA of 19% (IQR: 57 to -20%), -12% (23 to -38%), and -73% (-55 to -83%), respectively. The correlation coefficient for all sites was 0.17 (p = 0.003), and it was 0.16 (p = 0.07), 0.18 (p = 0.04), and 0.20 (p = 0.21) for small-intestinal (n = 137), pancreatic (n = 123), and unknown primary NET (n = 40), respectively. In the 58 patients showing tumor progression, the sensitivity and specificity of an increased CgA concentration were 36 and 82%, respectively, with positive and negative predictive values of 32 and 85%. Conclusions: In this prospective study of gastroenteropancreatic NET patients, we observed only a weak association between a change in plasma CgA and changes in tumor burden. CgA as a single biomarker was thus inadequate to predict tumor progression.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gronbaek, HenningAarhus Univ Hosp, Dept Gastroenterol & Hepatol, Neuroendocrine Tumour Ctr Excellence, DK-8200 Aarhus N, Denmark. (författare)
  • Sorbye, HalfdanHaukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Clin Sci, Bergen, Norway. (författare)
  • Evensen, Espen ThiisOslo Univ Hosp, Rigshosp, Dept Transplantat Med, Neuroendocrine Tumor Ctr Excellence, Oslo, Norway. (författare)
  • Paulsson, BjornNovartis Sverige AB, Kista, Sweden. (författare)
  • Sundin, Anders,1954-Uppsala universitet,Radiologi,Uppsala Univ Hosp, Neuroendocrine Tumor Ctr Excellence, Uppsala, Sweden.(Swepub:uu)anderssu (författare)
  • Jensen, ClausRigshosp, Neuroendocrine Tumour Ctr Excellence, Dept Radiol, Copenhagen, Denmark. (författare)
  • Ebbesen, DyvekeAarhus Univ Hosp, Neuroendocrine Tumour Ctr Excellence, Dept Radiol, Aarhus, Denmark. (författare)
  • Knigge, UlrichRigshosp, Neuroendocrine Tumour Ctr Excellence, Dept Endocrinol, Copenhagen, Denmark.;Rigshosp, Neuroendocrine Tumour Ctr Excellence, Dept Surg Gastroenterol, Copenhagen, Denmark. (författare)
  • Tiensuu Janson, EvaUppsala universitet,Onkologisk endokrinologi(Swepub:uu)evatieja (författare)
  • Aarhus Univ Hosp, Dept Gastroenterol & Hepatol, Neuroendocrine Tumour Ctr Excellence, DK-8200 Aarhus N, Denmark.Haukeland Hosp, Dept Oncol, Bergen, Norway.;Univ Bergen, Clin Sci, Bergen, Norway. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neuroendocrinology: S. Karger AG110:3/4, s. 217-2240028-38351423-0194

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy